Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Change in Account Payables (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Change in Account Payables data on record, last reported at $753000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 94.34% year-over-year to $753000.0; the TTM value through Dec 2025 reached $27.1 million, up 79.65%, while the annual FY2025 figure was $45.6 million, 279.62% up from the prior year.
  • Change in Account Payables reached $753000.0 in Q4 2025 per PAHC's latest filing, up from -$4.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $28.3 million in Q1 2025 and bottomed at -$9.0 million in Q4 2022.
  • Average Change in Account Payables over 5 years is $3.0 million, with a median of $2.0 million recorded in 2024.
  • The widest YoY moves for Change in Account Payables: up 1409.44% in 2022, down 1188.52% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $13.3 million in 2021, then tumbled by 167.58% to -$9.0 million in 2022, then skyrocketed by 176.95% to $6.9 million in 2023, then soared by 91.74% to $13.3 million in 2024, then plummeted by 94.34% to $753000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $753000.0 in Q4 2025, -$4.6 million in Q3 2025, and $2.6 million in Q2 2025.